Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04183595Phase 2Recruiting

NBMI Treatment in Patients With Mercury Toxicity

Role: lead

NCT04184063Phase 2Completed

Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)

Role: lead

NCT04092205Phase 2Completed

Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation

Role: lead

NCT02486289Phase 2Completed

Pilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication

Role: lead

NCT03123692Phase 2Completed

NBMI - Clinical Study on COPD

Role: lead

All 5 trials loaded